A dispute has arisen in the Risperdal litigation in Philadelphia over whether new plaintiffs in the mass tort should have to include prescription records and documentation of a Risperdal-related injury in their plaintiff fact sheets.
The defendant in the case, Janssen Pharmaceuticals, raised the issue, arguing it will help the courts weed out nonmeritorious claims, but plaintiffs have countered the requirement would create a “pseudo-summary judgment procedure” that would bypass the usual process.
